KRAS and pancreatic neoplasm: Alternately, we identified a subpopulation with differential response to selumetinib for a small proportion of KRAS NSCLC cell lines, but this subpopulation contained a higher proportion of colorectal and pancreatic cancer cells with KRAS mutations.